Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1434-9949
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis ; volume:41 ; number:9 ; day:26 ; month:5 ; year:2022 ; pages:2755-2763 ; date:9.2022
Clinical rheumatology ; 41, Heft 9 (26.5.2022), 2755-2763, 9.2022
- Urheber
-
Pellicano, Chiara
Campagna, Roberta
Oliva, Alessandra
Leodori, Giorgia
Miglionico, Marzia
Colalillo, Amalia
Mezzaroma, Ivano
Mastroianni, Claudio Maria
Turriziani, Ombretta
Rosato, Edoardo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10067-022-06219-7
- URN
-
urn:nbn:de:101:1-2022120121073716384449
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pellicano, Chiara
- Campagna, Roberta
- Oliva, Alessandra
- Leodori, Giorgia
- Miglionico, Marzia
- Colalillo, Amalia
- Mezzaroma, Ivano
- Mastroianni, Claudio Maria
- Turriziani, Ombretta
- Rosato, Edoardo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod